Literature DB >> 8820265

FK506 in the treatment of inflammatory skin disease: promises and perspectives.

G Michel1, L Kemeny, B Homey, T Ruzicka.   

Abstract

The immunosuppressive macrolide drug FK506 is currently gaining increasing importance in dermatopharmacology. Here, Gunter Michel and colleagues summarize the current state of research into the molecular mechanisms responsible for the functional modulation of cell types other than T cells, particularly epidermal cells, by this drug.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8820265     DOI： 10.1016/0167-5699(96)80599-8

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  4 in total

Review 1.  Treatment of the extraintestinal manifestations of inflammatory bowel disease.

Authors:  Charles N Bernstein
Journal:  Curr Gastroenterol Rep       Date:  2002-12

2.  Melanotransferrin gene expression in melanoma cells is correlated with high levels of Jun/Fos family transcripts and with the presence of a specific AP1-dependent ternary complex.

Authors:  A Rozé-Heusse; M L Houbiguian; C Debacker; M M Zakin; N Duchange
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

3.  A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes.

Authors:  D Bruch-Gerharz; K Fehsel; C Suschek; G Michel; T Ruzicka; V Kolb-Bachofen
Journal:  J Exp Med       Date:  1996-11-01       Impact factor: 14.307

4.  Phage p1-derived artificial chromosomes facilitate heterologous expression of the FK506 gene cluster.

Authors:  Adam C Jones; Bertolt Gust; Andreas Kulik; Lutz Heide; Mark J Buttner; Mervyn J Bibb
Journal:  PLoS One       Date:  2013-07-11       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.